A Study of Neoadjuvant FOLFIRINOX and FDR-Gemcitabine With Concurrent IMRT in Patients
Status:
Completed
Trial end date:
2019-08-30
Target enrollment:
Participant gender:
Summary
The investigators hypothesize that the combination of the FOLFIRINOX regimen (a combination
of 5-fluorouracil, irinotecan and oxaliplatin chemotherapy) to provide maximal systemic
disease control and FDR-gemcitabine chemotherapy with concurrent IMRT (Radiation therapy) to
address local disease, will achieve a significant improvement R0 resection (Radiation
oncology repeat surgeries) rate in borderline resectable (surgical) pancreatic cancer and
enhance disease free and overall survival in this patient population.
Phase:
Phase 2
Details
Lead Sponsor:
University of Michigan Cancer Center University of Michigan Rogel Cancer Center